ATLANTA, April 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has signed an exclusive three-year agreement with Minneapolis-based Medafor, Inc. Under terms of the agreement CryoLife will distribute Medafor's microporous polysaccharide hemostatic agent for use in cardiac and vascular surgery in the U.S. and for cardiac, vascular and general surgery, other than orthopaedic and ear, nose and throat surgery, outside the U.S. (excluding Japan and China).
CryoLife expects to begin distributing Hemostase MPH in the U.S. in the second quarter of 2008, except to approximately 41 hospitals for which Medafor will retain distribution rights until no later than December 31, 2008. Outside of the U.S., CryoLife expects to begin distributing Hemostase MPH in Canada, United Kingdom and Germany in the second quarter of 2008, with distribution in other markets beginning in 2009. Department of Defense hospitals are excluded from CryoLife's territory under the distribution agreement, but Veterans' Administration Hospitals are included.
The unique, absorbable powder hemostat, which received CE Mark approval in 2003 and FDA pre-market approval in September 2006, will be distributed by CryoLife under the private label name Hemostase MPH.
Hemostase MPH is developed using Medafor's exclusive, licensed Microporous Polysaccharide Hemospheres technology (MPH(R)), which yields a plant-based, flowable powder engineered to rapidly dehydrate blood, enhancing clotting on contact. When used as directed, this highly effective hemostatic agent facilitates the formation of a resilient, natural clot within just a few minutes.
Available in a convenient ready-to-use applicator, Hemostase MPH, unlike many hemostatic agents, does not require additional preparation steps in the operating room or special storage conditions thereby saving valuable operating room time and resources. Pre-clinical evaluations have shown that Hemostase MPH does not promote infection and absorbs within 24-48 hours of application at the wound site, compared to other surgical hemostats which can take 3-8 weeks or more to fully break down.
"Hemostase MPH gives surgeons the ability to quickly control active surgical bleeding, making it the perfect complement to CryoLife's BioGlue(R) product line, which is much stronger and provides both tissue reinforcement and sealant capabilities," stated Steven G. Anderson, president and chief executive officer. "Hemostase MPH also allows us to compete in the surgical hemostat market, which we believe totaled approximately $380 million in the U.S. in 2007."
Gary Shope, Medafor's chief executive, said, "We are pleased to be working with CryoLife as a major distribution partner. CryoLife is a world leader in its chosen areas, and its strength in sales, marketing and distribution in the cardio and vascular fields should provide great impetus to Medafor's market penetration."
The agreement allows for a three-year extension at the option of CryoLife if certain minimum purchases are met.
About CryoLife, Inc.
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company recently received FDA clearance for its CryoValve(R) SG pulmonary human heart valve, processed using CryoLife's proprietary SynerGraft(R) Technology. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community.
About Medafor Inc.
Medafor is a privately held Minneapolis based medical device company that has commercialized a naturally absorbent starch based hemostatic powder engineered to rapidly dehydrate blood and enhance clotting. This powder, which is Medafor's microporous polysaccharide hemostatic agent, has been commercialized for use in both intra-operative surgical procedures as well as numerous topical applications worldwide. This agent has a number of cost and safety features important to both surgeons and patients. The Company received FDA approval for surgical use of this product in September 2006 and has had CE Mark approval since 2003.
Statements made in this press release that look forward in time or that
express management's beliefs, expectations or hopes are forward-looking
statements within the meaning of the Private Securities Litigation Reform
Act of 1995. These statements include those regarding the ability of the
Company to begin distributing the Hemostase MPH product when expected, the
ability of the Company to compete in the surgical hemostat market, and
expectations regarding the market penetration of Hemostase MPH. These
future events may not occur as and when expected, if at all, and, together
with the Company's business, are subject to various risks and
uncertainties. These risks and uncertainties include that the Company may
be unable to effectively leverage its existing sales force to sell a new
product, that surgeons may not choose to utilize Hemostase MPH, and that
Hemostase MPH may not perform as expected or provide all expected benefits.
In addition, the Company's business is subject to the following risks: the
Company's strategic directives may not generate anticipated revenue and
earnings growth, that the Company is dependent on revenues from BioGlue,
competitive pressures and tissue availability may adversely affect the
Company's ability to grow revenues, the Company's efforts to develop and
introduce new products outside the U.S. may be unsuccessful, the Company's
efforts to improve procurement and tissue processing yields may not
continue to prove effective, the possibility that the FDA or foreign
regulatory bodies could impose restrictions on the Company's operations,
require a recall, or prevent the Company from processing and distributing
tissues or manufacturing and distributing other products, FDA and other
approvals for products in development may not be obtained, and if obtained,
may be costly and require lengthy review periods, products and services
under development may not be commercially feasible, CryoValve SG may not
perform as well as expected or provide all the benefits anticipated, demand
for CryoValve SG may not reach anticipated levels, and accordingly, the
Company may choose not to process the majority of its pulmonary valves with
the Company's SynerGraft technology, the SynerGraft post-clearance study
requested by the FDA may not provide the expected positive results, that
the Company's products and the tissues the Company processes allegedly have
caused and may in the future cause injury to patients and the Company has
been and may be exposed to product liability claims and additional
regulatory scrutiny as a result, that uncertainties related to patents and
protection of proprietary technology may affect the availability, amount
and timing of the Company's revenues, that pending or future litigation
cannot be settled on terms acceptable to the Company, that the Company may
not have sufficient resources to pay punitive damages (which are not
covered by insurance) or other liabilities in excess of its available
insurance, that the Company may not have sufficient borrowing or other
capital availability to fund its business, that the Company may be unable
to obtain sufficient financing to fully pursue its strategic plan and
future healthcare policies, healthcare reimbursement methods and healthcare
reimbursement policies may affect the availability, amount and timing of
the Company's revenues. These risks and uncertainties include the risk
factors detailed in CryoLife's Securities and Exchange Commission filings,
including CryoLife's Form 10-K filing for the year ended December 31, 2007
and the Company's other SEC filings. The Company does not undertake to
update its forward-looking statements.
For additional information about the company, visit CryoLife's Web site
D. Ashley Lee Katie Brazel
Executive Vice President, Chief Financial Officer Fleishman Hillard
and Chief Operating Officer Phone: 404-739-0150
|SOURCE CryoLife, Inc.|
Copyright©2008 PR Newswire.
All rights reserved